Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (Tulip SC)

First posted May, 2021, Updated September, 2021; Recruiting
CATEGORIES: Lupus

The purpose of this Phase 3 study is evaluating the efficacy and safety of SC anifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy.

To Learn More Contact
AstraZeneca Clinical Study Information Center at 1-877-240-9479 or email information.center@astrazeneca.com

ClinicalTrials.gov identifier (NCT number): NCT04877691